Vivos (OTC market code: RDGL) has received Investigational Device Exemption (IDE) approval from the US Food and Drug Administration (FDA) and will initiate a human clinical feasibility study of its Radiogel® Precision Radionuclide Therapy™.

BUZZ - Reports indicate that Nvidia's board is preparing to remove CEO Jensen Huang, causing the company's stock price to plummet.

CoreWeave (CRWV.US) to raise at least $4 billion after raising revenue guidance: AI computing power provider begins credit leap from "junk" to "investment grade"

MSCI to remove Strategy from global indexes in updated version, potentially putting billions of dollars in inflows at risk

Brazil proposes fiscal adjustment plan of up to 10.8 billions dollars, aiming to cut tax incentives and tighten spending